Sopharma AD-Sofia (WAR:SPH) Construction In Progress: zł70 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:SPH Sopharma AD-Sofia WAR:SPH
69 GF Score
Price zł9.70
GF Value zł8.61
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Construction In Progress?

Sopharma AD-Sofia WAR:SPH +8.99% 69 Construction In Progress is zł70 Mil as of Jun. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 69/100 and a GF Value™ of zł8.61 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Sopharma AD-Sofia's quarterly construction in progress increased from Dec. 2025 (zł57 Mil) to Mar. 2026 (zł57 Mil) and increased from Mar. 2026 (zł57 Mil) to Jun. 2026 (zł70 Mil).

Sopharma AD-Sofia's annual construction in progress increased from Dec. 2023 (zł15 Mil) to Dec. 2024 (zł35 Mil) and increased from Dec. 2024 (zł35 Mil) to Dec. 2025 (zł57 Mil).

Sopharma AD-Sofia Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Construction In Progress Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.25 10.98 14.57 35.00 57.02

Sopharma AD-Sofia Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.15 46.61 57.02 57.45 69.70
WAR:SPH
69GF Score
Sopharma AD-Sofia WAR:SPH
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of zł70 Mil mean?
Sopharma AD-Sofia (WAR:SPH) has a Construction In Progress of zł70 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Construction In Progress too high?
Sopharma AD-Sofia's current Construction In Progress is zł70 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Construction In Progress compare to MCK and COR?
Sopharma AD-Sofia's Construction In Progress of zł70 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Distribution company?
A good Construction In Progress depends on the Medical Distribution industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Construction In Progress is zł70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Modestly Overvalued. The stock's GF Value™ is zł8.61, compared to a current price of zł9.70 — trading 12.7% above its estimated fair value. The current Construction In Progress is zł70 Mil. Sopharma AD-Sofia's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Construction In Progress is zł70 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued. The current stock price of zł9.70 is trading 12.7% above its estimated GF Value™ of zł8.61. GuruFocus considers Sopharma AD-Sofia to be Modestly Overvalued.

Key valuation signals for WAR:SPH:

  • Construction In Progress: zł70 Mil
  • GF Value™: zł8.61 vs. price of zł9.70 (12.7% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
69GF Score

Get the complete analysis for WAR:SPH

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł9.70
Price
zł8.61
GF Value